Role of Ocular Angiogenic Factors in the Development of Neovascular Age-Related Macular Degeneration
-
Published:2020-06-01
Issue:3
Volume:74
Page:159-164
-
ISSN:1407-009X
-
Container-title:Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
-
language:en
-
Short-container-title:
Author:
Briede Elīza12, Baumane Kristīne12, Krūmiņa Angelika13
Affiliation:
1. Rīga East University Hospital , 2 Hipokrata Str ., Rīga , LV-1082 , Latvia 2. Residency Development Programme , University of Latvia , 19 Raina Blvd., Rīga, LV-1050 , Latvia 3. Department of Infectology , Rīga Stradiņš University , 16 Dzirciema Str. , Rīga , LV-1007 , Latvia
Abstract
Abstract
Age-related macular degeneration (AMD) is a progressive degenerative eye disease. Neovascular age-related macular degeneration (nAMD) is the advanced form of AMD characterised by abnormal growth of newly formed blood vessels in chorioidea which typically involves fluid accumulation in the retina or retinal haemorrhage, retinal epithelial detachments, hard exudate or subretinal scars. The process of angiogenesis is controlled by ocular angiogenic factors, which have enabled the development of different treatment options aimed at these factors. This review aims to compile the available information about the most commonly identified ocular angiogenic factors, uncovering their role in the pathogenesis of nAMD and assessing their application possibilities as biomarkers of disease identification and treatment.
Publisher
Walter de Gruyter GmbH
Subject
Multidisciplinary
Reference54 articles.
1. Ahn, J. K., Moon, H. J. (2009). Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration. Amer. J. Ophthalmol., 148, 718–724.10.1016/j.ajo.2009.06.012 2. Anonymous (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 69, 89–95. 3. Askou, A. L., Alsing, S., Benckendorff, J. N. E., Holmgaard, A., Mikkelsen, J. G., Aagaard, L., Bek, T., Corydon, T. J. (2019). Suppression of choroidal neovascularization by AAV-based dual-acting antiangiogenic gene therapy. Mol. Ther. Nucl. Acids, 16, 38–50.10.1016/j.omtn.2019.01.012 4. Bai, Y., Liang, S., Yu, W., Zhao, M., Huang, L., Zhao, M., Li, X. (2014). Semaphorin 3A blocks the formation of pathologic choroidal neovascularization induced by transforming growth factor beta. Mol. Vision, 20, 1258–1270. 5. Bakri, N. M., Ramachandran, V., Kee, H. F., Subrayan, V., Isa, H., Ngah, N. F., Mohamad, N. A., Mooi, C. S., Mun, C. Y., Ismail, P., Ismail, F., Sukiman, E. S., Sulaiman, W. A. W. (2018). Copy number variation in VEGF gene as a biomarker of susceptibility to age-related macular degeneration. Egypt. J. Med. Hum. Gen.,19, 207–213.10.1016/j.ejmhg.2017.09.003
|
|